Articles

Poll

Podcasts

Slideshows

Videos

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

The phase 3 data reinforce iptacopan’s safety and efficacy in C3G and support its recent US Food and Drug Administration approval for this indication.

APPEAR-C3G: Iptacopan Shows Proteinuria Reduction, eGFR Benefits in C3G

The Q3 recap for nephrology spotlights key FDA decisions, new KDIGO IgA nephropathy guidelines, and other top renal news and research.

Q3 2025 Recap: Nephrology News and Updates

Q3 2025 saw several new first targeted therapies for rare and more individualized indications in a number of fields.

Q3 2025 Recap: 7 Top FDA Approvals to Know

C3G Breakthroughs: First FDA-Approved Targeted Therapies Redefine Care

Nester describes the evolving C3G therapeutic landscape, the value of now having pegcetacoplan to offer patients, and trial data supporting its approval.

Entering A New Era of C3G Care with Pegcetacoplan, with Carla Nester, MD

In the final segment of this 5-part HCPLive RX Review, experts discuss real-world barriers to implementing new C3G therapies and lingering unmet needs.

Unmet Needs and Unanswered Questions in C3G

In part 4 of this 5-part HCPLive RX Review, experts discuss how the availability of new therapeutic options are changing the treatment paradigm in C3G.

Approaching Incident C3G in an Era of Targeted Therapies

In part 3 of this 5-part HCPLive RX Review, experts discuss VALIANT data supporting pegcetacoplan’s approval and how they compare to iptacopan.

Understanding Pegcetacoplan in C3G with VALIANT Data

In part 2 of this 5-part HCPLive RX Review, experts discuss how to utilize the newly FDA-approved therapies for treating C3G and what questions remain.

Navigating Targeted Therapies for C3 Glomerulopathy

In part 1 of this 5-part HCPLive RX Review, experts discuss the current therapeutic landscape for C3G following 2 notable FDA approvals.

A New Era for C3G Treatment with Pegcetacoplan

The HCPLive C3 glomerulopathy page is a resource for medical news and expert insights on C3G. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in C3G, and more.